Browse result page of CancerPDF Database
Please click on CancerPDF_ID for detailed information about peptide.
| CancerPDF_ID | Peptide seq | Protein Name | Fluid | Mass/Z | Profiling Technique | Cancer Type | Expression Regulation | PUBMED ID |
|---|---|---|---|---|---|---|---|---|
| CancerPDF_ID95 | NLGHGHKHERDQGHGHQ | HMW Kininogen | Serum | 1943.88 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID96 | KHNLGHGHKHERDQGHGHQ | HMW Kininogen | Serum | 2209.08 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID97 | GHGLGHGHEQQHGLGHGHKF | HMW Kininogen | Serum | 2126.94 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID98 | SRIGEIKEETTSHL | Kininogen-1 | Serum | 533.92 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID737 | SSRIGEIKEETTSHLR | Kininogen-1 | Plasma | 614.99 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID738 | IGEIKEETTSHLR | Kininogen-1 | Plasma | 504.93 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID739 | RPPGFSPFR | Kininogen-1 | Plasma | 530.78 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID740 | RPPGFSPF | Kininogen-1 | Plasma | 452.74 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID741 | DDDLEHQGGHVLDHGHKH | Kininogen-1 | Plasma | 682.64 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID742 | DDDLEHQGGHVLDHGH | Kininogen-1 | Plasma | 594.25 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID743 | DDDLEHQGGHVLDH | Kininogen-1 | Plasma | "793.84, 529.56" | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID1092 | NLGHGHKHERDQGHGHQ | HMW Kininogen | Serum | 1943.88 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.58, 141 and 1 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1093 | KHNLGHGHKHERDQGHGHQ | HMW Kininogen | Serum | 2209.08 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.72, 2.07 and 1.56 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1094 | GHGLGHGHEQQHGLGHGHKF | HMW Kininogen | Serum | 2126.94 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | NA | 16395409 |
| CancerPDF_ID1887 | PPGFSPFR | Kininogen-1 | Serum | 903.46029 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1888 | ITEATKTVG | Kininogen-1 | Serum | 918.50221 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1889 | RPPGFSPFR | Kininogen-1 | Serum | 1059.5614 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1890 | RPPGFSPFR | Kininogen-1 | Serum | 1059.5614 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1891 | QRQVVAGLNF | Kininogen-1 | Serum | 1130.61964 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1892 | AQRQVVAGLNF | Kininogen-1 | Serum | 1201.65676 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1893 | AQRQVVAGLNFR | Kininogen-1 | Serum | 1357.75787 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1894 | RHDWGHEKQR | Kininogen-1 | Serum | 1347.65446 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1895 | LDDDLEHQGGHVLDHGH | Kininogen-1 | Serum | 1892.84015 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1896 | FKLDDDLEHQGGHVLDHGH | Kininogen-1 | Serum | 2168.00353 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID1897 | RPPGFSPF | Kininogen-1 | Serum | 903.46029 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID3223 | EHQGGHV | Kininogen-1 | Plasma | 762.3409 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3224 | HGHGHGKH | Kininogen-1 | Plasma | 865.4056 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3225 | RPPGFSPF | Kininogen-1 | Plasma | 903.4603 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3226 | RPPGFSPFR | Kininogen-1 | Plasma | 1059.5614 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3227 | AQRQVVAGLNF | Kininogen-1 | Plasma | 1201.6568 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3228 | RHDWGHEKQR | Kininogen-1 | Plasma | 1347.6545 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3229 | LDDDLEHQGGHVLDHGH | Kininogen-1 | Plasma | 1892.8402 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3230 | LDDDLEHQGGHVLDHGHK | Kininogen-1 | Plasma | 2020.9351 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3231 | HNLGHGHKHERDQGHGHQ | Kininogen-1 | Plasma | 2079.9596 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3232 | GHGLGHGHEQQHGLGHGHKF | Kininogen-1 | Plasma | 2126.0055 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3233 | LDDDLEHQGGHVLDHGHKH | Kininogen-1 | Plasma | 2157.994 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3234 | KHNLGHGHKHERDQGHGHQ | Kininogen-1 | Plasma | 2208.0546 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3235 | FKLDDDLEHQGGHVLDHGHK | Kininogen-1 | Plasma | 2296.0985 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3236 | FKLDDDLEHQGGHVLDHGHKH | Kininogen-1 | Plasma | 2433.1574 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3237 | FKLDDDLEHQGGHVLDHGHKHK | Kininogen-1 | Plasma | 2561.2524 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID4349 | AQYDCLGCVHPI | Isoform LMW of Kininogen-1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID4534 | CVGCPRDIPTNSPELEETLTHTITKL | Isoform LMW of Kininogen-1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6150 | LYRITEATKTVGSDTFY | Isoform LMW of Kininogen-1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6515 | QESQSEEIDCNDKDLFKAV | Isoform LMW of Kininogen-1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6516 | QESQSEEIDCNDKDLFKAVDA | Isoform LMW of Kininogen-1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6539 | QITPAEGPVVTAQYDCLGCVHPI | Isoform LMW of Kininogen-1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID6676 | RITEATKTVGSDTFY | Isoform LMW of Kininogen-1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID7150 | STQSPDLEPILRHG | Isoform LMW of Kininogen-1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8092 | VVPWEKKIYPTVNCQPLGMIS | Isoform LMW of Kininogen-1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8265 | YEIKEGDCPVQSGKTWQDCEY | Isoform LMW of Kininogen-1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
| CancerPDF_ID8583 | KHNLGHGHKHERDQGHGHQ | Kininogen HMW | Serum | 2208.05 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8584 | NLGHGHKHERDQGHGHQ | Kininogen HMW | Serum | 1942.9 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8585 | GHGLGHGHEQQHGLGHGHKF | Kininogen HMW | Serum | 2126.01 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8616 | HNLGHGHKHERDQGHGHQ | Isoform HMW of kininogen-1 (KNG1) precursor | Serum | 2082.04 | MALDI-TOF | Breast cancer | Upregulated in cancer as compare to normal control with fold change of 1.9 | 26705257 |
| CancerPDF_ID8631 | RPPGFSPF | "kininogen L,high MW" | Plasma | 904.53 | MALDI-TOF | Cervical cancer | Uniquely present in cervical cancer | 24416269 |
| CancerPDF_ID8641 | NLGHGHKHERDQGHGHQ | "Kininogen L,high MW" | Plasma | 1943.93 | MALDI-TOF | Cervical cancer | Differential expression | 24416269 |
| CancerPDF_ID8642 | HNLGHGHKHERDQGHGHQ | "Kininogen L,high MW" | Plasma | 2080.98 | MALDI-TOF | Cervical cancer | Differential expression | 24416269 |
| CancerPDF_ID8643 | KHNLGHGHKHERDQGHGHQ | "Kininogen L,high MW" | Plasma | 2209.06 | MALDI-TOF | Cervical cancer | Downregulated in cancer vs normal | 24416269 |
| CancerPDF_ID8735 | DCLGCVHPIS | Isoform LMW of Kininogen-1 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8736 | DCPVQSGKTWQDCEY | Isoform LMW of Kininogen-1 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8846 | FSQNCDIYPGKDF | Isoform LMW of Kininogen-1 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9450 | RPPGFSPF | Des-Arg9 Bradykinin | Plasma | 904.46 | MALDI-TOF | Colorectal cancer | Higher median intensity for liver metastasis group and lower median intensity for adenoma and CRC groups than the controls. | 26379225 |
| CancerPDF_ID9454 | RPPGFSPFR | Bradykinin | Plasma | 1060.57 | MALDI-TOF | Colorectal cancer | Higher median intensity for liver metastasis group and lower median intensity for adenoma and CRC groups than the controls. | 26379225 |
| CancerPDF_ID9455 | RPPGFSPFR | oxidated Bradykinin | Plasma | 1076.56 | MALDI-TOF | Colorectal cancer | Higher median intensity for liver metastasis group and lower median intensity for adenoma and CRC groups than the controls. | 26379225 |
| CancerPDF_ID9463 | RHDWGHEKQR | Kininogen-1 | Plasma | 1348.63 | MALDI-TOF | Colorectal cancer | Not significant in annova test | 26379225 |
| CancerPDF_ID9491 | KHNLGHGHKHERDQGHGHQR | Kininogen-1 | Plasma | 2365.22 | MALDI-TOF | Colorectal cancer | "Low expression in control and liver metastatis group as comapred to adenoma, early,late CRC group." | 26379225 |
| CancerPDF_ID9835 | DDDLEHQ | Kininogen-1 | Serum | 436.16 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9836 | DDDLEHQGGH | Kininogen-1 | Serum | 561.72 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9837 | DDDLEHQGGHVLDH | Kininogen-1 | Serum | 529.56 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9838 | KHNLGHGHKHERDQGHGHQ | Kininogen-1 | Serum | 737.02 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9935 | RPPGFSPFR | Kininogen-1 | Serum | NA | LC-MS | Breast cancer | Differentially expressed between cancer vs control | 21124649 |
| CancerPDF_ID9936 | RPPGFSPFR | Kininogen-1 | Serum | NA | LC-MS | Breast cancer | Differentially expressed between cancer vs control | 21124649 |
| CancerPDF_ID9937 | RPPGFSPF | Kininogen-1 | Serum | NA | LC-MS | Breast cancer | NA | 21124649 |
| CancerPDF_ID9968 | RPPGFSPFR | Kininogen-1 | Urine | 1060.5946 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID9979 | PILRHGIQY | Kininogen-1 | Urine | 1096.616 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10128 | VKRAQRQVVAGLN | Kininogen-1 | Urine | 1438.8527 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10264 | NEVKRAQRQVVAGLN | Kininogen-1 | Urine | 1681.9347 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10273 | AALKKYNSQNQSNNQ | Kininogen-1 | Urine | 1707.8399 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10301 | GHGHEQQHGLGHGHKF | Kininogen-1 | Urine | 1762.8371 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10353 | AALKKYNSQNQSNNQF | Kininogen-1 | Urine | 1854.8953 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10444 | AALKKYNSQNQSNNQFVL | Kininogen-1 | Urine | 2067.0617 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10459 | VKKARVQVVAGKKYFIDF | Kininogen-1 | Urine | 2096.2324 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10502 | FKIDNVKKARVQVVAGKKY | Kininogen-1 | Urine | 2191.2944 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10630 | FKIDNVKKARVQVVAGKKYFIDF | Kininogen-1 | Urine | 2713.547 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10778 | KRPPGFSPFR | Kininogen-1 | Urine | 1204.6522 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID12742 | RPPGFSPF | Kininogen-1 | Serum | 904.5017 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.29 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.40, Upregulated in BC vs healthy with 0.902 fold change" | 27058005 |
| CancerPDF_ID12743 | RPPGFSPFR | Kininogen-1 | Serum | 1060.627 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.79 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.82, Upregulated in BC vs healthy with 0.818 fold change" | 27058005 |
| CancerPDF_ID12744 | GHKHERDQGHGHQ | Kininogen-1 | Serum | 1522.838 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.81 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.88, Upregulated in BC vs healthy with 1.118 fold change" | 27058005 |
| CancerPDF_ID12745 | HGHKHERDQGHGHQ | Kininogen-1 | Serum | 1659.808 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.47 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.65, Upregulated in BC vs healthy with 1.231 fold change" | 27058005 |
| CancerPDF_ID12746 | GHGHKHERDQGHGHQ | Kininogen-1 | Serum | 1716.955 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.25 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.11, Upregulated in BC vs healthy with 1.154 fold change" | 27058005 |
| CancerPDF_ID12747 | NLGHGHKHERDQGHGHQ | Kininogen-1 | Serum | 1943.95 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.45 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.43, Upregulated in BC vs healthy with 1.386 fold change" | 27058005 |
| CancerPDF_ID12748 | HGLGHGHEQQHGLGHGHKF | Kininogen-1 | Serum | 2070.011 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.25 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.62, Upregulated in BC vs healthy with 1.201 fold change" | 27058005 |
| CancerPDF_ID12749 | HNLGHGHKHERDQGHGHQ | Kininogen-1 | Serum | 2081.006 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.43 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.71, Upregulated in BC vs healthy with 1.565 fold change" | 27058005 |
| CancerPDF_ID12750 | GHGLGHGHEQQHGLGHGHKF | Kininogen-1 | Serum | 2127.055 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.10 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.48, Upregulated in BC vs healthy with 1.279 fold change" | 27058005 |
| CancerPDF_ID12751 | KHNLGHGHKHERDQGHGHQ | Kininogen-1 | Serum | 2209.11 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.31 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.29, Upregulated in BC vs healthy with 1.499 fold change" | 27058005 |
| CancerPDF_ID12752 | KHNLGHGHKHERDQGHGHQR | Kininogen-1 | Serum | 2365.208 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.62 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.87, Upregulated in BC vs healthy with 1.340 fold change" | 27058005 |
| CancerPDF_ID12996 | RPPGFSPF | Kininogen-1 | Plasma | 904.468 | ?LC-MS | "Multiple myeloma patients, Acute myeloid leukemia" | NA | 20974924 |
| CancerPDF_ID12997 | RPPGFSPF | Kininogen-1 | Plasma | 904.468 | ?LC-MS | "Multiple myeloma patients, Acute myeloid leukemia" | NA | 20974924 |
| CancerPDF_ID13904 | HDWGHEKQR | Kininogen-1 | Plasma | 1192.561 | ?LC-MS | "Multiple myeloma patients, Acute myeloid leukemia" | NA | 20974924 |
| CancerPDF_ID13996 | RPPGFSPFR | Kininogen-1 | Plasma | 1060.569 | ?LC-MS | "Multiple myeloma patients, Acute myeloid leukemia" | NA | 20974924 |